Published in Nature on January 04, 1990
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol (1992) 5.78
Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol (1993) 4.83
Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci U S A (1990) 4.80
Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci U S A (1991) 4.23
Quantitative polymerase chain reaction analysis of herpes simplex virus DNA in ganglia of mice infected with replication-incompetent mutants. J Virol (1990) 3.05
Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol (1994) 3.01
Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation. J Virol (1992) 2.86
Identification of shared populations of human immunodeficiency virus type 1 infecting microglia and tissue macrophages outside the central nervous system. J Virol (2001) 2.62
Human immunodeficiency virus type 1 T-cell tropism is determined by events prior to provirus formation. J Virol (1990) 2.11
Grossly defective nef gene sequences in a human immunodeficiency virus type 1-seropositive long-term nonprogressor. J Virol (1998) 1.99
Localization of simian immunodeficiency virus in the central nervous system of rhesus monkeys. Am J Pathol (1991) 1.93
Viral genetic determinants of T-cell killing and immunodeficiency disease induction by the feline leukemia virus FeLV-FAIDS. J Virol (1991) 1.83
Analysis of long terminal repeat circle junctions of human immunodeficiency virus type 1. J Virol (1990) 1.80
Fate of the human immunodeficiency virus type 1 provirus in infected cells: a role for vpr. J Virol (1995) 1.69
Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol (2005) 1.68
Human immunodeficiency virus type 1 replication in the absence of integrase-mediated dna recombination: definition of permissive and nonpermissive T-cell lines. J Virol (2001) 1.63
Early transcription from nonintegrated DNA in human immunodeficiency virus infection. J Virol (2003) 1.57
Unintegrated lentivirus DNA persistence and accessibility to expression in nondividing cells: analysis with class I integrase mutants. J Virol (2004) 1.56
Accumulation and intranuclear distribution of unintegrated human immunodeficiency virus type 1 DNA. J Virol (2001) 1.53
Viral complementation allows HIV-1 replication without integration. Retrovirology (2008) 1.52
Human immunodeficiency virus type 1 tropism for brain microglial cells is determined by a region of the env glycoprotein that also controls macrophage tropism. J Virol (1992) 1.52
Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage. Retrovirology (2010) 1.51
Evidence for gene expression by unintegrated human immunodeficiency virus type 1 DNA species. J Virol (2004) 1.49
HIV-1 transcription and latency: an update. Retrovirology (2013) 1.49
Human macrophages support persistent transcription from unintegrated HIV-1 DNA. Virology (2007) 1.46
Early viral replication in the brain of SIV-infected rhesus monkeys. Am J Pathol (1991) 1.42
TAR-independent transactivation by Tat in cells derived from the CNS: a novel mechanism of HIV-1 gene regulation. EMBO J (1992) 1.39
HIV-1 gene expression: lessons from provirus and non-integrated DNA. Retrovirology (2004) 1.36
The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. Microbiol Rev (1995) 1.34
Magnetic nanoformulation of azidothymidine 5'-triphosphate for targeted delivery across the blood-brain barrier. Int J Nanomedicine (2010) 1.31
Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion. Antimicrob Agents Chemother (1992) 1.27
Unintegrated human immunodeficiency virus type 1 DNA in chronically infected cell lines is not correlated with surface CD4 expression. J Virol (1991) 1.26
The role of unintegrated DNA in HIV infection. Retrovirology (2011) 1.23
Formation of simian immunodeficiency virus long terminal repeat circles in resting T cells requires both T cell receptor- and IL-2-dependent activation. J Exp Med (1995) 1.21
Human immunodeficiency virus type 1 expression in the central nervous system correlates directly with extent of disease. Proc Natl Acad Sci U S A (1990) 1.19
Detection of human immunodeficiency virus type 1 by using the polymerase chain reaction and a time-resolved fluorescence-based hybridization assay. J Clin Microbiol (1991) 1.18
Absence of DICER in monocytes and its regulation by HIV-1. J Biol Chem (2010) 1.15
HIV-1 latency in monocytes/macrophages. Viruses (2014) 1.13
Eradication of HIV from the brain: reasons for pause. AIDS (2011) 1.10
Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol (1999) 1.10
Low levels of human immunodeficiency virus replication in the brain tissue of children with severe acquired immunodeficiency syndrome encephalopathy. Am J Pathol (1992) 1.08
Eradication of HIV-1 from the macrophage reservoir: an uncertain goal? Viruses (2015) 1.07
NF-kappa B activates the HIV promoter in neurons. EMBO J (1993) 1.06
High-efficiency transduction of human lymphoid progenitor cells and expression in differentiated T cells. J Virol (1997) 1.03
Impact of dosing schedule upon suppression of a retrovirus in a murine model of AIDS encephalopathy. Antimicrob Agents Chemother (1994) 1.00
A rapid procedure for the quantitation of low abundance RNAs by competitive reverse transcription-polymerase chain reaction. Nucleic Acids Res (1994) 1.00
Update on HIV-associated neurocognitive disorders. Curr Neurol Neurosci Rep (2013) 0.99
Vpr is required for efficient Nef expression from unintegrated human immunodeficiency virus type 1 DNA. J Virol (2007) 0.97
PCR detection of HIV proviral DNA (gag) in the brains of patients with AIDS: comparison between results using fresh frozen and paraffin wax embedded specimens. J Clin Pathol (1994) 0.95
Effect of 3'-azido-3'-deoxythymidine on human immunodeficiency virus type 1 replication in human fetal brain macrophages. Antimicrob Agents Chemother (1993) 0.95
Rate and severity of HIV-associated dementia (HAD): correlations with Gp41 and iNOS. Mol Med (1999) 0.94
An HIV-1 replication pathway utilizing reverse transcription products that fail to integrate. J Virol (2013) 0.94
Expression of Nef from unintegrated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-lymphocytes. Retrovirology (2010) 0.91
The second chance story of HIV-1 DNA: Unintegrated? Not a problem! Retrovirology (2008) 0.91
Retroviral DNA Integration. Chem Rev (2016) 0.90
Molecular Understanding of HIV-1 Latency. Adv Virol (2012) 0.90
Localization of HIV RNA in mitochondria of infected cells: potential role in cytopathogenicity. J Cell Biol (1994) 0.89
Methods for gene transfer to the central nervous system. Adv Genet (2014) 0.88
Unintegrated bovine leukemia virus DNA: association with viral expression and disease. J Virol (1996) 0.85
Eradication of human immunodeficiency virus from brain reservoirs. J Neurovirol (2014) 0.84
HIV-1 infection of monocyte-derived macrophages reduces Fc and complement receptor expression. Clin Exp Immunol (1994) 0.83
A mechanism of restricted human immunodeficiency virus type 1 expression in human glial cells. J Virol (1996) 0.82
HIV-1 latency and virus production from unintegrated genomes following direct infection of resting CD4 T cells. Retrovirology (2016) 0.81
Human immunodeficiency virus type 1 Vpu and cellular TASK proteins suppress transcription of unintegrated HIV-1 DNA. Virol J (2012) 0.76
Peripheral blood lymphocyte HIV DNA levels correlate with HIV associated neurocognitive disorders in Nigeria. J Neurovirol (2017) 0.75
Magnetic Nanoparticles Cross the Blood-Brain Barrier: When Physics Rises to a Challenge. Nanomaterials (Basel) (2015) 0.75
Quantification of HIV DNA in the brain by PCR: differences between fresh frozen and formalin fixed tissue. J Clin Pathol (1996) 0.75
Distribution and fate of HIV-1 unintegrated DNA species: a comprehensive update. AIDS Res Ther (2017) 0.75
Modeling brain lentiviral infections during antiretroviral therapy in AIDS. J Neurovirol (2017) 0.75
HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment. J Neurol (2017) 0.75
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell (1990) 17.60
Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science (1987) 12.77
Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science (1985) 10.71
HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature (1990) 9.72
Cardiopulmonary resuscitation skills of preregistration house officers. Br Med J (Clin Res Ed) (1985) 8.45
Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol (1992) 5.78
Cerebral amyloid angiopathy. A critical review. Stroke (1987) 4.56
The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol (1995) 4.42
Mitochondrial abnormalities in Alzheimer's disease. J Neurosci (2001) 4.39
Complete nucleotide sequence of an infectious clone of human T-cell leukemia virus type II: an open reading frame for the protease gene. Proc Natl Acad Sci U S A (1985) 4.28
Clearance of HIV infection in a perinatally infected infant. N Engl J Med (1995) 3.76
Embolization of arteriovenous malformations with Onyx: clinicopathological experience in 23 patients. Neurosurgery (2001) 3.49
The SCID-hu mouse as a model for HIV-1 infection. Nature (1993) 3.43
Identification of the putative transforming protein of the human T-cell leukemia viruses HTLV-I and HTLV-II. Science (1984) 3.39
Transformation of human leukocytes by cocultivation with an adult T cell leukemia virus producer cell line. Science (1982) 3.37
Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages. J Virol (1991) 3.28
Cytokines alter production of HIV-1 from primary mononuclear phagocytes. Science (1988) 3.22
Human cytomegalovirus productively infects primary differentiated macrophages. J Virol (1991) 3.16
Rev is necessary for translation but not cytoplasmic accumulation of HIV-1 vif, vpr, and env/vpu 2 RNAs. Genes Dev (1991) 3.06
High rate of HTLV-II infection in seropositive i.v. drug abusers in New Orleans. Science (1989) 3.00
Terminology and classification of the cortical dysplasias. Neurology (2004) 2.99
The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biol (2000) 2.89
Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. Stroke (1984) 2.86
Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J Virol (1997) 2.82
Analysis of rev gene function on human immunodeficiency virus type 1 replication in lymphoid cells by using a quantitative polymerase chain reaction method. J Virol (1989) 2.67
Nucleotide sequence analysis of the long terminal repeat of human T-cell leukemia virus type II. Proc Natl Acad Sci U S A (1984) 2.67
Tumor promoter, TPA, enhances replication of HTLV-III/LAV. Virology (1986) 2.51
Characterization of reticuloendotheliosis virus strain T DNA and isolation of a novel variant of reticuloendotheliosis virus strain T by molecular cloning. J Virol (1981) 2.49
Identification of the gene responsible for human T-cell leukaemia virus transcriptional regulation. Nature (1986) 2.49
The region of the envelope gene of human immunodeficiency virus type 1 responsible for determination of cell tropism. J Virol (1992) 2.49
Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity. J Virol (1994) 2.45
The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. JAMA (1997) 2.45
The x gene is essential for HTLV replication. Science (1985) 2.44
Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor. J Virol (1989) 2.42
Human T-cell leukemia virus type II transforms normal human lymphocytes. Proc Natl Acad Sci U S A (1983) 2.41
Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic T-cell line Molt-4. J Virol (1986) 2.40
Long terminal repeats of human T-cell leukaemia virus II genome determine target cell specificity. Nature (1984) 2.39
Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. Biochemistry (2000) 2.37
HIV-1 production from infected peripheral blood T cells after HTLV-I induced mitogenic stimulation. Science (1988) 2.37
Molecular characterization of genome of a novel human T-cell leukaemia virus. Nature (1983) 2.36
Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors. J Virol (1994) 2.36
Vpr-induced cell cycle arrest is conserved among primate lentiviruses. J Virol (1996) 2.33
Cerebral hemispherectomy: hospital course, seizure, developmental, language, and motor outcomes. Neurology (2004) 2.30
Increased susceptibility of differentiated mononuclear phagocytes to productive infection with human immunodeficiency virus-1 (HIV-1). J Clin Invest (1992) 2.28
Localization of tuberous sclerosis 2 mRNA and its protein product tuberin in normal human brain and in cerebral lesions of patients with tuberous sclerosis. Brain Pathol (1996) 2.27
Establishment of infection by spleen necrosis virus: inhibition in stationary cells and the role of secondary infection. J Virol (1982) 2.26
Evidence for fibromuscular pulleys of the recti extraocular muscles. Invest Ophthalmol Vis Sci (1995) 2.26
Removing interictal fast ripples on electrocorticography linked with seizure freedom in children. Neurology (2010) 2.23
Genetic analysis of human immunodeficiency virus type 1 integrase and the U3 att site: unusual phenotype of mutants in the zinc finger-like domain. J Virol (1995) 2.22
A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci U S A (1993) 2.15
Deoxycytidine kinase from calf thymus. Substrate and inhibitor specificity. J Biol Chem (1976) 2.14
Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids. J Nat Prod (1994) 2.12
Binding of host-cell factors to DNA sequences in the long terminal repeat of human T-cell leukemia virus type I: implications for viral gene expression. Proc Natl Acad Sci U S A (1988) 2.12
Human immunodeficiency virus type 1 T-cell tropism is determined by events prior to provirus formation. J Virol (1990) 2.11
A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. J Virol (2001) 2.11
Nucleotide sequence of the 3' region of an infectious human T-cell leukemia virus type II genome. Proc Natl Acad Sci U S A (1984) 2.10
A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med (1997) 2.09
Rapid generation of sequence variation during primary HIV-1 infection. AIDS (1992) 2.08
The neuropathology of AIDS. UCLA experience and review. Am J Pathol (1986) 2.08
HTLV-II in patients with HTLV-I-associated myelopathy. Lancet (1991) 2.04
Do state licensing procedures discriminate against physicians using mental health services? One physician calls for reform. Minn Med (1997) 2.01
High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol (1997) 2.00
Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis. Medicine (Baltimore) (1991) 1.89
Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med (1990) 1.89
Functional relation between HTLV-II x and adenovirus E1A proteins in transcriptional activation. Science (1985) 1.87
The National NeuroAIDS Tissue Consortium: a new paradigm in brain banking with an emphasis on infectious disease. Neuropathol Appl Neurobiol (2001) 1.86
Cell cycle arrest by Vpr in HIV-1 virions and insensitivity to antiretroviral agents. Science (1998) 1.83
Occupational asthma caused by automated salmon processing. Lancet (1995) 1.80
Phenotypic variability of Gerstmann-Sträussler-Scheinker disease is associated with prion protein heterogeneity. J Neuropathol Exp Neurol (1998) 1.79
Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol (2000) 1.76
HIV-1 env sequence variation in brain tissue of patients with AIDS-related neurologic disease. J Acquir Immune Defic Syndr (1991) 1.72
Nonadhesive liquid embolic agent for cerebral arteriovenous malformations: preliminary histopathological studies in swine rete mirabile. Neurosurgery (1998) 1.72
Structure of a human DNA repair protein UBA domain that interacts with HIV-1 Vpr. Nat Struct Biol (1998) 1.69
Fate of the human immunodeficiency virus type 1 provirus in infected cells: a role for vpr. J Virol (1995) 1.69
Substitution of 5' helper virus sequences into non-rel portion of reticuloendotheliosis virus strain T suppresses transformation of chicken spleen cells. Cell (1982) 1.69
Antibody to caspase-cleaved actin detects apoptosis in differentiated neuroblastoma and plaque-associated neurons and microglia in Alzheimer's disease. Am J Pathol (1998) 1.67
Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4. J Virol (1992) 1.66
HIV-1, macrophages, glial cells, and cytokines in AIDS nervous system disease. FASEB J (1991) 1.66
Studies of the putative transforming protein of the type I human T-cell leukemia virus. Science (1985) 1.65
CD4-independent, productive infection of a neuronal cell line by human immunodeficiency virus type 1. J Virol (1990) 1.64
Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor. Proc Natl Acad Sci U S A (1991) 1.62
Hepatitis C virus RNA in saliva. Lancet (1990) 1.62
An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication. J Virol (1999) 1.61
Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier. Eur J Clin Invest (2002) 1.61
Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation. J Virol (2000) 1.61
FDG-PET/MRI coregistration improves detection of cortical dysplasia in patients with epilepsy. Neurology (2008) 1.59
Point substitution in the central hydrophobic cluster of a human beta-amyloid congener disrupts peptide folding and abolishes plaque competence. Biochemistry (1996) 1.58
Incomplete resection of focal cortical dysplasia is the main predictor of poor postsurgical outcome. Neurology (2008) 1.57
Regulation of AIDS virus expression. Cell (1986) 1.57
Posterior cortical atrophy. Neuropathologic correlations. Arch Neurol (1994) 1.56
Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology (1998) 1.55